Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss

Summary

With this clinical trial the investigators will analyze whether the rate of pregnancy losses before the 24th week of gestation can be reduced by dalteparin treatment in habitual aborters.

Timeline

Start

2006-11

Primary completion

2012-12

Completion

2013-04

Outcome

Missed primary endpoint

paper CONCLUSION: Daily LMWH injections do not increase ongoing pregnancy or live-birth rates in women with unexplained RPL. PMID 25938990 ↗

Publications

• Middleton P, Shepherd E, Gomersall JC. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2021 Mar 29;3(3):CD001689. doi: 10.1002/14651858.CD001689.pub4.
• Rogenhofer N, Markoff A, Wagner A, Klein HG, Petroff D, Schleussner E; EThIG II Group; Thaler CJ. Lessons From the EThIGII Trial: Proper Putative Benefit Assessment of Low-Molecular-Weight Heparin Treatment in M2/ANXA5 Haplotype Carriers. Clin Appl Thromb Hemost. 2017 Jan;23(1):27-33. doi: 10.1177/1076029616658117. Epub 2016 Jul 14.
• Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B, Schenk M, Henes M, Bohlmann MK, Fischer T, Brosteanu O, Bauersachs R, Petroff D; ETHIG II group. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med. 2015 May 5;162(9):601-9. doi: 10.7326/M14-2062.

Drugs

Indications